Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $7.00 at Benchmark

Reviva Pharmaceuticals (NASDAQ:RVPH) had its price objective decreased by Benchmark from $14.00 to $7.00 in a research report sent to investors on Monday morning,Benzinga reports. Benchmark currently has a speculative buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Wall Street Zen raised Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, August 16th. Roth Capital reissued a “buy” rating and set a $3.00 price objective (down previously from $7.00) on shares of Reviva Pharmaceuticals in a report on Monday, August 18th. Maxim Group decreased their price objective on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, August 15th. D. Boral Capital reaffirmed a “buy” rating and issued a $3.00 price target on shares of Reviva Pharmaceuticals in a research note on Monday, August 18th. Finally, Citigroup reiterated a “buy” rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $5.50.

Reviva Pharmaceuticals Stock Down 2.3%

Shares of RVPH stock opened at $0.43 on Monday. The stock has a 50-day simple moving average of $0.45 and a 200 day simple moving average of $0.70. Reviva Pharmaceuticals has a fifty-two week low of $0.30 and a fifty-two week high of $4.28. The stock has a market capitalization of $29.38 million, a P/E ratio of -0.66 and a beta of -0.04.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. On average, sell-side analysts anticipate that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of large investors have recently made changes to their positions in RVPH. Ameriprise Financial Inc. bought a new position in Reviva Pharmaceuticals during the 4th quarter worth $84,000. BluePointe Capital Management LLC boosted its holdings in shares of Reviva Pharmaceuticals by 354.7% during the 1st quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock valued at $45,000 after acquiring an additional 36,807 shares in the last quarter. Tang Capital Management LLC acquired a new position in Reviva Pharmaceuticals during the 4th quarter worth about $308,000. Private Advisor Group LLC acquired a new position in Reviva Pharmaceuticals during the 1st quarter worth about $191,000. Finally, Armistice Capital LLC acquired a new position in shares of Reviva Pharmaceuticals in the 2nd quarter valued at about $1,026,000. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.